Abstract:In the proposed intelligent biosensing drug‐induced cardiotoxicity assessment platform, the cardiomyocytes are treated with non‐cardiotoxic or cardiotoxic drugs to obtain mechanical beating signals. The beating signals are converted into image representations by phase space reconstruction and analyzed by convolutional neural network to identify the cardiotoxicity of drugs. Drug‐induced cardiotoxicity often leads to patient deaths and drug recalls. Interdigitated electrode (IDE)‐based cellular impedance detection instrument has been integrated with intelligent algorithms to screen cardiotoxicity based on cardiomyocytes. These intelligent biosensing systems generally employ traditional machine learning methods to assess drug‐induced cardiotoxicity by analyzing cardiomyocytes mechanical beating signals. However, modern deep learning methods with robustness and flexibility have not been integrated in IDE‐based platform to screen cardiotoxicity. Here, for the first time, we implemented deep convolutional neural network (CNN) to analyze cardiomyocytes mechanical beating signals for cardiotoxicity assessment. This method can eliminate the feature engineering procedures, such as manual design and extraction of signal features required by traditional machine learning methods. To facilitate two‐dimensional (2‐D) CNN analysis, we utilized phase space reconstruction to convert one‐dimensional beating signals into 2‐D image representations as well as take into account nonlinear dynamic information. The phase space reconstruction‐assisted convolutional neural network (PSRCNN) is capable of accurately categorizing drug‐induced cardiotoxicities and predicting cardiotoxicity levels. It obtains accuracies ranging from 0.82 to 0.99 when recognizing the cardiotoxicity of newly developed drugs, which are represented by drugs that are not used during model training. Furthermore, we explore in depth to compare the performance of CNN with other traditional machine learning methods. The PSRCNN method can achieve higher accuracies when compared to other methods. The PSRCNN‐based biosensing platform is highly potential in improving the efficiency and accuracy of high‐throughput screening of newly developed drugs for cardiotoxicity during drug discovery.

Three-Dimensional Cardiomyocyte-Nanobiosensing System for Specific Recognition of Drug Subgroups

Beating Cardiac Cell-Based Biosensor and Its Application in Drugs Screening

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Cardiac Cell-based Biosensor and Its Biomedical Applications

Three-dimensional cardiomyocyte-based biosensor with tissue engineering scaffold

3D Cell-Based Biosensor for Cell Viability and Drug Assessment by 3D Electric Cell/matrigel-Substrate Impedance Sensing.

High-temporal-range Drug-Induced Cardiac Side-Effect Evaluation Using Simultaneous HL-1-based Impedance and Long-Term Electrophysiology Recording Systems

Integrated Cell-Based Biosensor for Extracellular Electrophysiological Monitoring

Electromechanical Integrated Recording of Single Cardiomyocyte in Situ by Multimodal Microelectrode Biosensing System.

A Biosensing System Using a Multiparameter Nonlinear Dynamic Analysis of Cardiomyocyte Beating for Drug-Induced Arrhythmia Recognition

Universal and Sensitive Drug Assessment Biosensing Platform Using Optimal Mechanical Beating Detection of Single Cardiomyocyte

Multifunctional cardiac microphysiological system based on transparent ITO electrodes for simultaneous optical measurement and electrical signal monitoring

Synchronized High-Content Recording of Cardiomyocytes in Vitro by Integrated Cell-Based Biosensor

An intelligent biosensing platform using phase space reconstruction‐assisted convolutional neural network for drug‐induced cardiotoxicity assessment

Cardiomyocyte electrical-mechanical synchronized model for high-content, dose-quantitative and time-dependent drug assessment

Drug evaluations using a novel microphysiometer based on cell-based biosensors

A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating.

Micronano Synergetic Three-Dimensional Bioelectronics: A Revolutionary Breakthrough Platform for Cardiac Electrophysiology

Multifunctional Cardiomyocyte-Based Biosensor For Electrophysiology-Mechanical Beating-Growth Viability Monitoring

Specific recognition of ion channel blocker by high-content cardiomyocyte electromechanical integrated correlation

Advances in Multidimensional Cardiac Biosensing Technologies: From Electrophysiology to Mechanical Motion and Contractile Force